Diplomat Pharmacy (DPLO) Tops Q2 EPS by 2c

Diplomat Pharmacy (NYSE: DPLO) reported Q2 EPS of $0.23, $0.02 better than the analyst estimate of $0.21. Revenue for the quarter came in at $1.09 billion versus the consensus estimate of $1.12 billion.

GUIDANCE:

Diplomat Pharmacy sees FY2016 EPS of $0.90-$0.95, versus prior guidance of $0.88-$0.95 and the consensus of $0.93. Diplomat Pharmacy sees FY2016 revenue of $4.5-4.9 billion, versus the consensus of $4.76 billion.

For earnings history and earnings-related data on Diplomat Pharmacy (DPLO) click here.

You May Also Be Interested In

• Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
• Philip Morris International (PM) Tops Q1 EPS by 9c; raises guidance
• Northwest Bancshares, Inc. (NWBI) PT Lowered to $10 at Piper Sandler